← Back

MiMedx Group Inc

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Price · split & dividend adjusted
News & notes moving MDXG
MDXG▲

Monteverde & Associates investigates four mergers for potential shareholder claims

Monteverde & Associates PC is investigating four proposed acquisitions for potential breaches of fiduciary duty and other violations of law. The firm is examining the sale of Forte Biosciences to argenx BV at $77.00 per share in cash, Luxfer Holdings to affiliates of Wynnchurch Capital at $17.37 per share in cash, Sanara MedTech to MiMedx Group for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and MarketAxess Holdings to Intercontinental Exchange at $167.00 per share in cash. Shareholders are encouraged to contact the firm before the applicable tender offer deadlines, including August 26, 2026 for Forte Biosciences.
FBRX ▲ICE ▲LXFR ▲MDXG ▲MKTX ▲SMTI
GlobeNewswire·20dRead more ▾
Biotech & Genomic Medicine▲

SciSparc, Avantor, NeoGenomics Lead Biotech Gains on Milestones and Upgraded Outlooks

Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.
ALVO ▲AVTR ▲LBRX ▲MDXG ▲NEO ▲SMTI ▲+1
Biotech & Genomic Medicine ▲
RTTNews·28dRead more ▾
MDXG▼

MIMEDX Reports Second Quarter Net Sales of $64 Million and Plans to Acquire Sanara MedTech

MIMEDX announced second quarter 2026 net sales of $64 million, a 35% decline from the prior year, and separately unveiled a definitive agreement to acquire Sanara MedTech in a cash-and-stock deal valued at approximately $350 million. Surgical product sales grew 15% year-over-year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes that took effect on January 1. The company reported a net loss of $15 million for the quarter, compared to net income of $10 million a year earlier, and held $136 million in cash and equivalents as of June 30. MIMEDX reiterated its full-year 2026 net sales guidance of $260 to $290 million and expects Adjusted EBITDA to approach breakeven. Under the Sanara acquisition terms, Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock per share, representing a 46% premium to Sanara’s 30-day volume-weighted average price, with the transaction expected to close by year-end subject to shareholder and regulatory approvals.
MDXG ▼SMTI ▲
GlobeNewswire·28dRead more ▾
Biotech & Genomic Medicine▼

Regenerative Medicine Market Projected to Surpass $100 Billion Within a Decade

The regenerative medicine market is projected to surpass US$100 billion within roughly a decade, driven by a shift from tissue replacement to regeneration using biomaterials, cell therapies, and 3D bioprinting. Independent estimates place the broad market in the tens of billions of dollars in 2026, with compound annual growth rates frequently estimated in the high teens to mid-20s percent. Key drivers include aging populations, the diabetes epidemic, rising surgical volumes, and growing demand in aesthetics, partly fueled by GLP-1 weight-loss medications. The sector spans profitable commercial leaders like Integra LifeSciences and Vericel to early-stage platform companies such as Conexeu Sciences, which began trading on Nasdaq in May 2026 with its collagen-based extracellular-matrix platform. Reimbursement policy and regulatory pathways remain critical risks, as illustrated by recent upheaval in the U.S. skin-substitute market affecting companies like Organogenesis and MiMedx.
MDXG ▼ORGO ▼IART ▲VCEL ▲CNXU ▲
Biotech & Genomic Medicine ▲Aging Population ▲
GlobeNewswire·69dRead more ▾
© 2026 MarketDXAsset